Integra LifeSciences Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance
- The Q4 2023 revenues for Integra LifeSciences were $397.0 million, showing a 0.2% decrease compared to the same period in 2022.
- Full-year 2023 revenues for the company amounted to $1,541.6 million, reflecting a 1.0% decrease from the previous year.
- Adjusted earnings per diluted share for Q4 2023 were $0.89, down from $0.94 in the fourth quarter of 2022.
- For the full year 2023, adjusted earnings per diluted share were $3.10, compared to $3.36 in 2022.
- Integra LifeSciences highlighted successful business achievements, including the relaunch of Boston and the global CereLink relaunch with 510k clearance.
- The company also mentioned the completion of the SIA acquisition and the signing of a definitive agreement to acquire the Acclarent ENT business by Q2 2024.
- Revenue growth was noted in specific segments such as Neurosurgery, CSF management, and Instruments.
- The company reported a decrease in adjusted EBITDA for Q4 2023 compared to the same period in 2022.
- Cash flows from operations for Q4 were $58.7 million, with capital expenditures amounting to $24.6 million.
- Integra LifeSciences provided guidance for 2024, expecting revenues in the range of $1,603 million to $1,618 million and adjusted earnings per diluted share between $3.15 and $3.25.
- The company experienced a decrease in adjusted EBITDA for Q4 2023 compared to the previous year.
- Full-year 2023 revenues showed a 1.0% decrease from 2022.
- Adjusted earnings per diluted share for both Q4 2023 and full-year 2023 were lower than the respective periods in 2022.
Insights
Integra LifeSciences Holdings Corporation's Q4 and full-year financial performance indicates a marginal decline in reported and organic revenue, suggesting a potential tightening in the company's operational efficiency and market dynamics. The slight decrease in organic growth, including the exclusion of the Boston segment, reflects a need for a strategic review of their product mix and market penetration. The reported GAAP earnings per diluted share show a significant drop from the previous year, which could be indicative of increased cost pressures or one-time expenses impacting the bottom line.
The company's capital allocation strategy, with $275M in share repurchases, may signal confidence in long-term value creation from management, yet it's imperative to consider the impact of such buybacks on the company's leverage, especially with a net debt of $1.2 billion. Investors should assess the balance between returning capital to shareholders and investing in growth opportunities, particularly in light of the company's international expansion efforts and product portfolio developments like the CereLink® relaunch and the pending acquisition of Acclarent® ENT business.
Integra's performance in the Codman Specialty Surgical segment, which accounts for a majority of their revenue, shows resilience with reported increases in sales. This could be attributed to the growth in neurosurgery and dural repair products, which are likely driven by innovation and market demand for specialized surgical solutions. However, the Tissue Technologies segment's decline, exacerbated by the Boston product recall, raises concerns about the company's vulnerability to product-specific risks and the importance of maintaining a diverse and robust product pipeline to mitigate such impacts.
The guidance for 2024 suggests an optimistic outlook, with expected revenue growth and adjusted earnings per share increases. This forward-looking statement may reflect management's confidence in overcoming current challenges and capitalizing on market recovery. However, investors should be cautious and seek further clarity on how the company plans to achieve these targets amidst operational challenges and competitive pressures.
Integra's strategic moves, including the relaunch of products like CereLink® and the expansion of their international portfolio, indicate a proactive approach to maintaining market relevance and addressing regulatory hurdles, such as the EU Medical Device Regulation. The emphasis on building in-China-for-China manufacturing capabilities highlights a trend towards localization in response to global trade dynamics and may provide a competitive edge within the Chinese market.
The 510(k) clearance and the U.S. relaunch of products underscore the company's commitment to compliance and innovation in the highly regulated medical device industry. However, the impact of the Boston product recall on revenue underlines the critical nature of quality control and risk management in this sector. The successful integration of acquisitions like SIA and the advanced clinical strategy for products like SurgiMend® and DuraSorb® suggest a strategic focus on growth through both organic and inorganic means, which could bolster the company's market position if executed effectively.
PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2023.
Fourth Quarter 2023
- Reported revenues were
$397.0 million , representing a decrease of0.2% on a reported basis and a decrease of1.2% on an organic basis compared to the fourth quarter 2022. Revenue increased3.6% on an organic basis excluding Boston.
- GAAP earnings per diluted share were
$0.25 , compared to$0.63 in the fourth quarter 2022.
- Adjusted earnings per diluted share were
$0.89 , compared to$0.94 in the fourth quarter of 2022.
Full-Year 2023
- Reported revenues were
$1,541.6 million representing a decrease of1.0% on a reported basis and flat on an organic basis compared to full-year 2022. Revenue increased5.5% on an organic basis excluding Boston.
- GAAP earnings per diluted share were
$0.84 , compared to$2.16 in 2022.
- Adjusted earnings per diluted share were
$3.10 , compared to$3.36 in 2022.
Business Highlights
- Boston relaunch remains on track for mid-to-late Q2 2024
- Completed global CereLink® relaunch with 510k clearance and US relaunch in Q1 2024
- Successful integration of the SIA acquisition
- Advanced PMA clinical strategy for SurgiMend® and DuraSorb®
- International portfolio expansion of DuraGen®, CUSA®, and 100+ product registrations
- Building-out in-China-for-China manufacturing capability
- Obtained 510(k) for next generation Aurora® Surgiscope
- Signed definitive agreement to acquire the Acclarent® ENT business by Q2 2024
- Executed
$275M in share repurchases - Upgraded Quality Management System with investments in talent and process capabilities
"In 2023, we saw stability in our markets and resilience of our product portfolio, which demonstrates the impact of our products and technologies on restoring patients’ lives," said Jan De Witte, president and chief executive officer "Despite the operational challenges last year, I am extremely proud of our colleagues around the world for remaining focused on advancing our key pillars of growth and operational excellence, and for their unwavering commitment to our customers and patients.”
Fourth Quarter 2023 Financial Summary
Total reported revenues for the fourth quarter were 397.0 million, a decrease of
The Company reported GAAP net income of
Adjusted EBITDA for the fourth quarter of 2023 was
Adjusted net income for the fourth quarter of 2023 was
Cash flows from operations totaled
Fourth Quarter 2023 Segment Performance
- Codman Specialty Surgical (
69% of Revenues)- Total revenues were
$271.6 million , representing reported an increase of2.7% and organic growth of2.3% compared to the fourth quarter of 2022. Sales in Neurosurgery grew2.0% on an organic basis.- CSF management had mid-single digit growth driven by Certas® Plus valves.
- Mid-single-digit growth in dural access and repair driven by DuraGen, partially offset by a decline in DuraSeal.
- Neuro monitoring grew low-single digits driven by BactiSeal® catheters and ICP microsensors.
- Advanced energy was down by low-single digits driven by lower CUSA® capital sales.
- Sales in Instruments grew
3.0% on an organic basis.
- Total revenues were
- Tissue Technologies (
31% of Revenue)- Total revenues were
$125.4 million , representing a decrease of6.0% on a reported basis and organic decline of8.0% compared to the fourth quarter of 2022 due to the impact of the lost revenue related to the Boston product recall which was partially offset by double digit growth from BioD® and Gentrix® and mid-single digit growth in Integra skin and MediHoney®.
- Total revenues were
Full-Year 2023 Financial Summary
Total reported revenues for the full-year 2023 were
The Company reported GAAP net income of
Adjusted EBITDA for the full-year 2023 was
Adjusted net income for the full-year 2023 was
2023 Balance Sheet, Cash Flow and Capital Allocation
The Company generated cash flow from operations of
2024 Revenue and Adjusted Earnings Per Share Guidance
The Company’s guidance for 2024 revenue and adjusted earnings per share reflects the stability of our markets and strong demand for our differentiated portfolio, gradual improvement in supply over the year, continued international expansion and the relaunch of the Boston portfolio late second quarter. Our guidance excludes the pending acquisition of the Acclarent ENT business.
For the full-year 2024, the Company expects revenues to be in a range of
For the first quarter 2024, the Company expects reported revenues in the range of
Organic sales growth excludes acquisitions and divestitures as well as the effects of foreign currency.
The Company is providing forward-looking guidance regarding adjusted earnings per diluted share but is not providing a reconciliation to GAAP earnings per share, because certain GAAP expense items are highly variable, and management is unable to predict them with reasonable certainty and without unreasonable effort. Specifically, the financial impact and timing of divestitures, acquisitions, integrations, structural optimization and efforts to comply with the EU Medical Device Regulation are uncertain, depend on various dynamic factors and are not reasonably ascertainable at this time. These expense items could have a material impact on GAAP results.
Conference Call and Presentation Available Online
Integra has scheduled a conference call for 8:30 a.m. ET on Wednesday, February 28, 2024, to discuss fourth quarter and full-year 2023 financial results, and forward-looking financial guidance. The conference call will be hosted by Integra's senior management team and will be open to all listeners. Additional forward-looking information may be discussed in a question-and-answer session following the call. Integra's management team will reference a presentation during the conference call, which can be found on the Investor Relations section of the website at investor.integralife.com.
A live webcast will be available on the Investors section of the Company’s website at investor.integralife.com. For those planning to participate on the call, please register here to receive dial-in details and a unique pin. While not required, it is recommended to join 10 minutes prior to the start of the event. A webcast replay of the conference call will be available on the Investor Relations section of the Company’s website following the call.
About Integra
At Integra LifeSciences, we are driven by our purpose of restoring patients’ lives. We innovate treatment pathways to advance patient outcomes and set new standards of surgical, neurologic, and regenerative care. We offer a comprehensive portfolio of high quality, leadership brands that include AmnioExcel®, Aurora®, Bactiseal®, BioD™, CerebroFlo®, CereLink® Certas® Plus, Codman®, CUSA®, Cytal®, DuraGen®, DuraSeal®, DuraSorb®, Gentrix®, ICP Express®, Integra®, Licox®, MAYFIELD®, MediHoney®, MicroFrance®, MicroMatrix®, NeuraGen®, NeuraWrap™, PriMatrix®, SurgiMend®, TCC-EZ® and VersaTru®. For the latest news and information about Integra and its products, please visit www.integralife.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. Some of these forward-looking statements may contain words like “will,” “believe,” “may,” “could,” “would,” “might,” “possible,” “should,” “expect,” “intend,” "forecast," "guidance," “plan,” “anticipate,” "target," or “continue,” the negative of these words, other terms of similar meaning or they may use future dates. Forward-looking statements contained in this news release include, but are not limited to, statements concerning future financial performance, including projections for revenues, expected revenue growth (both reported and organic), GAAP and adjusted net income, GAAP and adjusted earnings per diluted share, non-GAAP adjustments such as divestiture, acquisition and integration-related charges, intangible asset amortization, structural optimization charges, EU Medical Device Regulation-related charges, charges related to the voluntary global recall of all products manufactured at the Company’s facility in Boston, Massachusetts, and income tax expense (benefit) related to non-GAAP adjustments and other items, expectations and plans with respect to strategic initiatives, product development and regulatory approvals and expectations concerning the resumption of manufacturing at the Company’s Boston, Massachusetts facility. It is important to note that the Company’s goals and expectations are not predictions of actual performance. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Such risks and uncertainties include, but are not limited, to the following: the ongoing and possible future effects of global challenges, including macroeconomic uncertainties, inflation, supply chain disruptions, trade regulation and tariffs, other economic disruptions and U.S. and global recession concerns, on the Company’s customers and on the Company’s business, financial condition, results of operations and cash flows; the Company's ability to execute its operating plan effectively; the Company’s ability to successfully integrate acquired businesses; the Company’s ability to achieve sales growth in a timely fashion; the Company's ability to manufacture and ship sufficient quantities of its products to meet its customers' demands; the ability of third-party suppliers to supply us with raw materials and finished products; global macroeconomic and political conditions, including the war in Ukraine and the conflict in Israel and Gaza; the Company's ability to manage its direct sales channels effectively; the sales performance of third-party distributors on whom the Company relies to generate revenue for certain products and geographic regions; the Company's ability to access and maintain relationships with customers of acquired entities and businesses; physicians' willingness to adopt and third-party payors' willingness to provide or maintain reimbursement for the Company's recently launched, planned and existing products; initiatives launched by the Company's competitors; downward pricing pressures from customers; the Company's ability to secure regulatory approval for products in development; the Company's ability to remediate quality systems violations; fluctuations in hospitals' spending for capital equipment; the Company's ability to comply with regulations regarding products of human origin and products containing materials derived from animal source; difficulties in controlling expenses, including costs to procure and manufacture our products; the impact of changes in management or staff levels; the impact of goodwill and intangible asset impairment charges if future operating results of acquired businesses are significantly less than the results anticipated at the time of the acquisitions, the Company's ability to leverage its existing selling organizations and administrative infrastructure; the Company's ability to increase product sales and gross margins, and control non-product costs; the Company’s ability to achieve anticipated growth rates, margins and scale and execute its strategy generally; the amount and timing of divestiture, acquisition and integration-related costs; the geographic distribution of where the Company generates its taxable income; new U.S. and foreign government laws and regulations, and changes in existing laws, regulations and enforcement guidance, which affect areas of our operations including, but not limited to, those affecting the health care industry, including the EU Medical Devices Regulation; the scope, duration and effect of additional U.S. and international governmental, regulatory, fiscal, monetary and public health responses to the COVID-19 pandemic and any future public health crises; fluctuations in foreign currency exchange rates; the amount of our bank borrowings outstanding and other factors influencing liquidity; potential negative impacts resulting from environmental, social and governance matters; and the economic, competitive, governmental, technological, and other risk factors and uncertainties identified under the heading “Risk Factors” included in Item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2023 to be filed with the Securities and Exchange Commission.
These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events, or otherwise.
Discussion of Adjusted Financial Measures
In addition to our GAAP results, we provide certain non-GAAP measures, including organic revenues, organic revenues excluding Boston, adjusted earnings before interest, taxes, depreciation and amortization ("EBITDA"), adjusted net income, adjusted earnings per diluted share, free cash flow, adjusted free cash flow conversion, and net debt. Organic revenues consist of total revenues excluding the effects of currency exchange rates, revenues from current-period acquisitions and product divestitures. Organic revenues excluding Boston consist of total revenues, excluding (i) the effects of currency exchange rates, revenues from current-period acquisitions and product divestitures and discontinuances and (ii) revenues associated with Boston produced products including sales reported prior to the recall and the impact of sales return provisions recorded. Adjusted EBITDA consists of GAAP net income excluding: (i) depreciation and amortization; (ii) other income (expense); (iii) interest income and expense; (iv) income tax expense (benefit); and (v) those operating expenses also excluded from adjusted net income. The measure of adjusted net income consists of GAAP net income, excluding: (i) structural optimization charges; (ii) divestiture, acquisition and integration-related charges; (iii) EU Medical Device Regulation-related charges; (iv) charges related to the voluntary global recall of products manufactured at the Company’s Boston, Massachusetts facility; (v) intangible asset amortization expense; and (vi) income tax impact from adjustments. The adjusted earnings per diluted share measure is calculated by dividing adjusted net income attributable to diluted shares by diluted weighted average shares outstanding. The measure of free cash flow consists of GAAP net cash provided by operating activities less purchases of property and equipment. The adjusted free cash flow conversion measure is calculated by dividing free cash flow by adjusted net income. The measure of net debt consists of GAAP total debt (excluding deferred financing costs) less short-term investments, cash and cash equivalents.
Reconciliations of GAAP revenues to organic revenues, GAAP revenues to organic revenues excluding Boston, and GAAP net income to adjusted EBITDA and adjusted net income, GAAP total debt to net debt, and GAAP earnings per diluted share to adjusted earnings per diluted share all for the quarters and years ended December 31, 2023 and 2022, and the free cash flow and adjusted free cash flow conversion for the quarters and years ended December 31, 2023 and 2022, appear in the financial tables in this release.
The Company believes that the presentation of organic revenues and the other non-GAAP measures provide important supplemental information to management and investors regarding financial and business trends relating to the Company's financial condition and results of operations. For further information regarding why Integra believes that these non-GAAP financial measures provide useful information to investors, the specific manner in which management uses these measures, and some of the limitations associated with the use of these measures, please refer to the Company's Current Report on Form 8-K regarding this earnings press release filed today with the Securities and Exchange Commission. This Current Report on Form 8-K is available on the SEC's website at www.sec.gov or on our website at www.integralife.com.
Investor Relations Contact:
Chris Ward
(609) 772-7736
chris.ward@integralife.com
Media Contact:
Laurene Isip
(609) 208-8121
laurene.isip@integralife.com
| INTEGRA LIFESCIENCES HOLDINGS CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) | |||||||||||
| (In thousands, except per share amounts) | |||||||||||
| Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||
| Total revenues | 397,039 | 398,022 | 1,541,573 | 1,557,666 | |||||||
| Costs and expenses: | |||||||||||
| Cost of goods sold | 170,546 | 147,937 | 656,838 | 587,355 | |||||||
| Research and development | 24,284 | 26,783 | 104,192 | 101,193 | |||||||
| Selling, general and administrative | 163,128 | 151,919 | 656,641 | 616,316 | |||||||
| Intangible asset amortization | 3,034 | 3,543 | 12,376 | 13,882 | |||||||
| Total costs and expenses | 360,992 | 330,182 | 1,430,047 | 1,318,746 | |||||||
| Operating income | 36,047 | 67,840 | 111,526 | 238,920 | |||||||
| Interest income | 4,549 | 5,311 | 17,202 | 11,917 | |||||||
| Interest expense | (13,751 | ) | (12,894 | ) | (51,377 | ) | (49,594 | ) | |||
| Gain (loss) from the sale of business | — | — | — | 644 | |||||||
| Other income, net | 2,013 | 3,951 | 3,718 | 12,007 | |||||||
| Income before taxes | 28,858 | 64,208 | 81,069 | 213,894 | |||||||
| Income tax expense (benefit) | 9,024 | 11,262 | 13,328 | 33,344 | |||||||
| Net income | 19,834 | 52,946 | 67,741 | 180,550 | |||||||
| Net income per share: | |||||||||||
| Diluted net income per share | 0.25 | 0.63 | 0.84 | 2.16 | |||||||
| Weighted average common shares outstanding for diluted net income per share | 77,959 | 83,568 | 80,337 | 83,516 | |||||||
Segment revenues and growth in total revenues excluding the effects of currency exchange rates, acquisitions and discontinued products are as follows:
(In thousands)
| Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||
| 2023 | 2022 | Change | 2023 | 2022 | Change | ||||||
| Neurosurgery | 210,204 | 205,199 | 818,101 | 794,017 | |||||||
| Instruments | 61,423 | 59,398 | 240,892 | 225,547 | |||||||
| Total Codman Specialty Surgical | 271,627 | 264,597 | 1,058,993 | 1,019,564 | |||||||
| Wound Reconstruction and Care | 93,859 | 102,540 | (8.5)% | 373,986 | 406,689 | (8.0)% | |||||
| Private Label | 31,553 | 30,885 | 108,594 | 131,413 | (17.4)% | ||||||
| Total Tissue Technologies | 125,412 | 133,425 | (6.0)% | 482,580 | 538,102 | (10.3)% | |||||
| Total Reported Revenues | 397,039 | 398,022 | (0.2)% | 1,541,573 | 1,557,666 | (1.0)% | |||||
| Impact of changes in currency exchange rates | (928 | ) | — | — | 6,817 | — | — | ||||
| Less contribution of revenues from acquisitions | (2,548 | ) | — | — | (9,753 | ) | — | — | |||
| Less contribution of revenues from divested products | — | (122 | ) | — | (245 | ) | (18,063 | ) | — | ||
| Less contribution of revenues from discontinued products | (2,068 | ) | (1,600 | ) | — | (6,604 | ) | (7,876 | ) | — | |
| Total organic revenues(1) | 391,496 | 396,300 | (1.2)% | 1,531,788 | 1,531,727 | —% | |||||
| Boston Revenue impact | (1,005 | ) | (19,543 | ) | (2,759 | ) | (83,077 | ) | |||
| Total Organic Revenues ex Boston | 390,491 | 376,756 | 1,529,029 | 1,448,650 | |||||||
(1) Organic revenues have been adjusted to exclude foreign currency (current period), acquisitions and to account for divested and discontinued products.
Items included in GAAP net income and from continuing operations and locations where each item is recorded are as follows:
(In thousands)
| Three Months Ended December 31, 2023 | |||||||||||||||||
| Item | Total Amount | COGS(a) | SG&A(b) | R&D(c) | Amort.(d) | OI&E(e) | Tax(f) | ||||||||||
| Acquisition, divestiture and integration-related charges | 7,117 | 73 | 8,040 | (880 | ) | — | (116 | ) | — | ||||||||
| Structural Optimization charges | 7,998 | 4,859 | 3,155 | (16 | ) | — | — | — | |||||||||
| EU Medical Device Regulation charges | 12,387 | 2,227 | 4,653 | 5,507 | — | — | — | ||||||||||
| Boston Recall | 6,346 | 5,587 | 759 | — | |||||||||||||
| Intangible asset amortization expense | 20,687 | 17,653 | — | — | 3,034 | — | — | ||||||||||
| Estimated income tax impact from above adjustments and other items | (5,272 | ) | — | — | — | — | — | (5,272 | ) | ||||||||
| Depreciation expense | 9,834 | — | — | — | — | — | — | ||||||||||
| (a) COGS - Cost of goods sold (b) SG&A - Selling, general and administrative (c) R&D - Research & development (d) Amort. - Intangible asset amortization (e) OI&E - Other income & expense (f) Tax - Income tax expense (benefit) | |||||||||||||||||
| Three Months Ended December 31, 2022 | ||||||||||||||||||
| Item | Total Amount | COGS(a) | SG&A(b) | R&D(c) | Amort.(d) | OI&E(e) | Tax(f) | |||||||||||
| Acquisition, divestiture and integration-related charges(1) | 704 | 619 | 620 | 477 | — | (1,013 | ) | — | ||||||||||
| Structural Optimization charges | (1,533 | ) | (4,195 | ) | 2,669 | (7 | ) | — | — | — | ||||||||
| EU Medical Device Regulation charges | 12,177 | 1,439 | 4,855 | 5,884 | — | — | — | |||||||||||
| Intangible asset amortization expense | 19,632 | 16,089 | — | — | 3,543 | — | — | |||||||||||
| Estimated income tax impact from above adjustments and other items | (5,091 | ) | — | — | — | — | — | (5,091 | ) | |||||||||
| Depreciation expense | 9,861 | — | — | — | — | — | — | |||||||||||
| (a) COGS - Cost of goods sold (b) SG&A - Selling, general and administrative (c) R&D - Research and development (d) Amort. - Intangible asset amortization (e) OI&E - Other income and expense (f) Tax - Income tax expense | ||||||||||||||||||
Items included in GAAP net income and location where each item is recorded are as follows:
(In thousands)
| Twelve Months Ended December 31, 2023 | |||||||||||||||||
| Item | Total Amount | COGS(a) | SG&A(b) | R&D(c) | Amort.(d) | OI&E(e) | Tax(f) | ||||||||||
| Acquisition, divestiture and integration-related charges | 25,173 | 3,045 | 25,181 | (2,188 | ) | — | (865 | ) | — | ||||||||
| Structural Optimization charges | 23,020 | 15,144 | 7,943 | (67 | ) | — | — | — | |||||||||
| EU Medical Device Regulation charges | 46,559 | 5,813 | 20,002 | 20,745 | — | — | — | ||||||||||
| Boston Recall | 40,034 | 39,181 | 853 | — | |||||||||||||
| Intangible asset amortization expense | 82,823 | 70,447 | — | — | 12,376 | — | — | ||||||||||
| Estimated income tax impact from above adjustments and other items | (37,573 | ) | — | — | — | — | — | (37,573 | ) | ||||||||
| Depreciation expense | 39,704 | — | — | — | — | — | — | ||||||||||
| (a) COGS - Cost of goods sold (b) SG&A - Selling, general and administrative (c) R&D - Research and development (d) Amort. - Intangible asset amortization (e) OI&E - Interest (income) expense, net and other (income), net (f) Tax - Income tax expense | |||||||||||||||||
| Twelve Months Ended December 31, 2022 | ||||||||||||||||||
| Item | Total Amount | COGS(a) | SG&A(b) | R&D(c) | Amort.(d) | OI&E(e) | Tax(f) | |||||||||||
| Acquisition, divestiture and integration-related charges | (18,849 | ) | 1,543 | (13,379 | ) | (2,195 | ) | — | (4,818 | ) | — | |||||||
| Structural Optimization charges | 23,072 | 5,554 | 17,368 | 150 | — | — | — | |||||||||||
| EU Medical Device Regulation charges | 45,147 | 4,626 | 16,596 | 23,926 | — | — | — | |||||||||||
| Intangible asset amortization expense | 78,295 | 64,413 | — | — | 13,882 | — | — | |||||||||||
| Estimated income tax impact from above adjustments and other items | (27,349 | ) | — | — | — | — | — | (27,349 | ) | |||||||||
| Depreciation expense | 39,943 | — | — | — | — | — | — | |||||||||||
| (a) COGS - Cost of goods sold (b) SG&A - Selling, general and administrative (c) R&D - Research and development (d) Amort. - Intangible asset amortization (e) OI&E - Interest (income) expense, net and other (income), net (f) Tax - Income tax expense | ||||||||||||||||||
| INTEGRA LIFESCIENCES HOLDINGS CORPORATION RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP NET INCOME FROM CONTINUING OPERATIONS TO ADJUSTED EBITDA (UNAUDITED) | |||||||||||
| (In thousands) | |||||||||||
| Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||
| GAAP net income | 19,834 | 52,946 | 67,741 | 180,550 | |||||||
| Non-GAAP adjustments: | |||||||||||
| Depreciation and intangible asset amortization expense | 30,522 | 29,493 | 122,528 | 118,238 | |||||||
| Other (income), net | (1,897 | ) | (2,938 | ) | (2,853 | ) | (7,833 | ) | |||
| Interest expense, net | 9,202 | 7,583 | 34,175 | 37,677 | |||||||
| Income tax expense (benefit) | 9,024 | 11,262 | 13,328 | 33,344 | |||||||
| Structural optimization charges | 7,998 | (1,533 | ) | 23,020 | 23,072 | ||||||
| EU Medical Device Regulation charges | 12,387 | 12,177 | 46,559 | 45,147 | |||||||
| Boston Recall | 6,346 | — | 40,034 | — | |||||||
| Acquisition, divestiture and integration-related charges | 7,117 | 704 | 25,173 | (18,849 | ) | ||||||
| Total of non-GAAP adjustments | 80,700 | 56,747 | 301,964 | 230,796 | |||||||
| Adjusted EBITDA | 100,534 | 109,693 | 369,705 | 411,346 | |||||||
| INTEGRA LIFESCIENCES HOLDINGS CORPORATION RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP NET INCOME FROM CONTINUING OPERATIONS TO MEASURES OF ADJUSTED NET INCOME AND ADJUSTED EARNINGS PER SHARE (UNAUDITED) | |||||||||||||||
| (In thousands, except per share amounts) | |||||||||||||||
| Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||
| GAAP net income | 19,834 | 52,946 | 67,741 | 180,550 | |||||||||||
| Non-GAAP adjustments: | |||||||||||||||
| Structural optimization charges | 7,998 | (1,533 | ) | 23,020 | 23,072 | ||||||||||
| Acquisition, divestiture and integration-related charges | 7,117 | 704 | 25,173 | (18,849 | ) | ||||||||||
| EU Medical Device Regulation charges | 12,387 | 12,177 | 46,559 | 45,147 | |||||||||||
| Boston Recall | 6,346 | — | 40,034 | — | |||||||||||
| Intangible asset amortization expense | 20,687 | 19,632 | 82,823 | 78,295 | |||||||||||
| Estimated income tax impact from adjustments and other items | (5,272 | ) | (5,091 | ) | (37,573 | ) | (27,349 | ) | |||||||
| Total of non-GAAP adjustments | 49,264 | 25,889 | 180,036 | 100,316 | |||||||||||
| Adjusted net income | $ | 69,098 | $ | 78,835 | $ | 247,777 | $ | 280,866 | |||||||
| Adjusted diluted net income per share | $ | 0.89 | $ | 0.94 | $ | 3.10 | $ | 3.36 | |||||||
| Weighted average common shares outstanding for diluted net income per share | 77,959 | 83,568 | 80,337 | 83,516 | |||||||||||
| INTEGRA LIFESCIENCES HOLDINGS CORPORATION CONDENSED BALANCE SHEET DATA (UNAUDITED) | ||||||||
| (In thousands) | ||||||||
| December 31, | December 31, | |||||||
| 2023 | 2022 | |||||||
| Cash and cash equivalents | $ | 276,402 | $ | 456,661 | ||||
| Accounts receivable, net | 259,327 | 263,465 | ||||||
| Inventory, net | 389,608 | 324,583 | ||||||
| Current and long-term borrowing under senior credit facility | 840,094 | 771,274 | ||||||
| Borrowings under securitization facility | 89,200 | 104,700 | ||||||
| Long-term convertible securities | 570,255 | 567,341 | ||||||
| Stockholders' equity | 1,587,884 | 1,804,403 | ||||||
| INTEGRA LIFESCIENCES HOLDINGS CORPORATION CONDENSED STATEMENT OF CASH FLOWS (UNAUDITED) | |||||||
| Twelve Months Ending December 31, | |||||||
| 2023 | 2022 | ||||||
| Net cash provided by operating activities | $ | 139,955 | $ | 264,469 | |||
| Net cash used in investing activities | (94,178 | ) | (58,580 | ) | |||
| Net cash used in by financing activities | (229,925 | ) | (251,953 | ) | |||
| Effect of exchange rate changes on cash and cash equivalents | 3,889 | (10,723 | ) | ||||
| Net increase (decrease) in cash and cash equivalents | (180,259 | ) | (56,787 | ) | |||
| RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP OPERATING CASH FLOW TO MEASURES OF ADJUSTED FREE CASH FLOW AND ADJUSTED FREE CASH FLOW CONVERSION (UNAUDITED) | ||||||
| (In thousands) | ||||||
| Three Months Ended December 31, | ||||||
| 2023 | 2022 | |||||
| GAAP Net cash provided by operating activities | $ | 58,746 | $ | 85,333 | ||
| Purchases of property and equipment | (24,563 | ) | (14,455 | ) | ||
| Adj. Free Cash Flow | $ | 34,183 | $ | 70,878 | ||
| Adjusted net income (1) | $ | 69,098 | 78,835 | |||
| Adjusted Free Cash Flow Conversion | 49.5 | % | 89.9 | % | ||
| Twelve Months Ending December 31, | ||||||
| 2023 | 2022 | |||||
| GAAP Net cash provided by operating activities | $ | 139,955 | $ | 264,469 | ||
| Purchases of property and equipment | (66,865 | ) | (42,343 | ) | ||
| Adj. Free Cash Flow | $ | 73,090 | $ | 222,127 | ||
| Adjusted net income (1) | $ | 247,777 | 280,867 | |||
| Adjusted Free Cash Flow Conversion | 29.5 | % | 79.1 | % | ||
(1) Adjusted net income for quarters and twelve months ended December 31, 2022 and 2023 are reconciled above. Adjusted net income for remaining quarters in the trailing twelve months calculation have been previously reconciled and are publicly available in the Quarterly Earnings Call Presentations on our website at investor.integralife.com.
The Company calculates adjusted free cash flow conversion by dividing its free cash flow by adjusted net income. The Company believes this measure is a useful metric in evaluating the significance of the cash special charges in its adjusted earnings measures.
| RECONCILIATION OF NON-GAAP ADJUSTMENTS - NET DEBT CALCULATION (UNAUDITED) | |||||||
| (In thousands) | |||||||
| December 31, 2023 | December 31, 2022 | ||||||
| Short-term borrowings under senior credit facility | $ | 14,531 | $ | 38,125 | |||
| Long-term borrowings under senior credit facility | 825,563 | 733,149 | |||||
| Borrowings under securitization facility | 89,200 | 104,700 | |||||
| Long-term convertible securities | 570,255 | 567,341 | |||||
| Deferred financing costs netted in the above | 9,651 | 11,385 | |||||
| Short-term investments | (32,694 | ) | — | ||||
| Cash & Cash Equivalents | (276,402 | ) | (456,661 | ) | |||
| Net Debt | $ | 1,200,104 | $ | 998,039 | |||
FAQ
What were Integra LifeSciences' (IART) reported revenues for Q4 2023?
How did Integra LifeSciences' (IART) full-year 2023 revenues compare to the previous year?
What were the adjusted earnings per diluted share for Integra LifeSciences (IART) in Q4 2023?
What guidance did Integra LifeSciences (IART) provide for 2024?
